Introduction#
Morgan Stanley has upgraded Compass Pathways (NASDAQ:CMPS) to an Overweight rating, setting a price target of $16.00. This comes after recent regulatory announcements from the FDA that have positively impacted the company's stock performance.
Stock Performance#
In the past week, Compass Pathways' stock surged by 37%, reaching $9.56, which is close to its 52-week high of $10.21. However, some analysts suggest that the stock may currently be overvalued compared to its estimated fair value.
FDA Regulatory Actions#
The FDA has taken significant steps to support the development of serotonin-2A agonists, including issuing Commissioner’s National Priority Vouchers (CNPV) for three psychedelic programs. Compass Pathways received a CNPV for its treatment, COMP360, aimed at addressing treatment-resistant depression. This framework is designed to speed up the development and review process while ensuring safety and efficacy standards are met.
Future Prospects#
Morgan Stanley anticipates that the rolling New Drug Application (NDA) submission for COMP360 could conclude after the results of a 26-week Phase 3 trial, expected in early Q3. The firm believes that approval for this treatment could be granted as soon as the end of 2026. The FDA's recent actions align with an Executive Order aimed at improving access to treatments for serious mental illnesses.
Partnerships and Additional Coverage#
In related news, Compass Pathways has partnered with Osmind to prepare psychiatric clinics for the potential rollout of its treatments, pending FDA approval. Additionally, B.Riley has initiated coverage with a Buy rating and a price target of $17.00, while BTIG has reaffirmed its Buy rating with a target of $14.00, citing the company's strong clinical trial performance and regulatory advantages. These developments highlight Compass Pathways' commitment to advancing its innovative treatments.